Xencor, Inc. (NASDAQ:XNCR) Shares Acquired by Primecap Management Co. CA

Primecap Management Co. CA increased its stake in shares of Xencor, Inc. (NASDAQ:XNCR) by 0.3% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 9,116,202 shares of the biopharmaceutical company’s stock after purchasing an additional 25,495 shares during the quarter. Primecap Management Co. CA owned approximately 14.78% of Xencor worth $172,570,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors have also recently added to or reduced their stakes in XNCR. Parallel Advisors LLC lifted its stake in shares of Xencor by 303.9% during the fourth quarter. Parallel Advisors LLC now owns 1,349 shares of the biopharmaceutical company’s stock valued at $29,000 after buying an additional 1,015 shares during the period. GAMMA Investing LLC raised its holdings in Xencor by 153.7% in the 1st quarter. GAMMA Investing LLC now owns 2,172 shares of the biopharmaceutical company’s stock valued at $48,000 after acquiring an additional 1,316 shares during the last quarter. Quest Partners LLC purchased a new position in shares of Xencor during the 4th quarter worth $61,000. Quadrant Capital Group LLC boosted its holdings in shares of Xencor by 475.2% during the fourth quarter. Quadrant Capital Group LLC now owns 4,757 shares of the biopharmaceutical company’s stock worth $101,000 after purchasing an additional 3,930 shares during the last quarter. Finally, SG Americas Securities LLC purchased a new stake in shares of Xencor in the second quarter valued at $154,000.

Insider Buying and Selling at Xencor

In other news, VP John R. Desjarlais sold 36,329 shares of Xencor stock in a transaction that occurred on Tuesday, July 9th. The shares were sold at an average price of $18.32, for a total transaction of $665,547.28. Following the sale, the vice president now owns 192,319 shares in the company, valued at $3,523,284.08. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 5.23% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

XNCR has been the topic of a number of research analyst reports. JPMorgan Chase & Co. decreased their price target on Xencor from $30.00 to $27.00 and set an “overweight” rating on the stock in a research note on Wednesday, July 31st. Wedbush restated an “outperform” rating and issued a $34.00 target price on shares of Xencor in a report on Monday, September 9th. Royal Bank of Canada reaffirmed an “outperform” rating and set a $31.00 price target on shares of Xencor in a research note on Tuesday, August 6th. Raymond James lowered their price objective on shares of Xencor from $58.00 to $40.00 and set a “strong-buy” rating for the company in a research note on Friday, June 14th. Finally, BMO Capital Markets reaffirmed an “outperform” rating and issued a $32.00 target price on shares of Xencor in a research report on Tuesday, August 6th. Two investment analysts have rated the stock with a hold rating, seven have issued a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $34.44.

Xencor Stock Down 1.5 %

Shares of NASDAQ XNCR opened at $21.15 on Tuesday. The stock has a fifty day moving average price of $18.43 and a 200 day moving average price of $20.48. The company has a current ratio of 6.92, a quick ratio of 6.92 and a debt-to-equity ratio of 0.02. Xencor, Inc. has a 12-month low of $15.31 and a 12-month high of $26.84. The company has a market cap of $1.31 billion, a P/E ratio of -9.66 and a beta of 0.66.

Xencor (NASDAQ:XNCR) last posted its earnings results on Monday, August 5th. The biopharmaceutical company reported ($1.07) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.82) by ($0.25). The company had revenue of $16.96 million during the quarter, compared to analyst estimates of $21.13 million. Xencor had a negative net margin of 132.74% and a negative return on equity of 28.23%. Xencor’s quarterly revenue was down 62.7% compared to the same quarter last year. During the same quarter last year, the business posted ($0.37) EPS. Research analysts anticipate that Xencor, Inc. will post -4.17 EPS for the current fiscal year.

About Xencor

Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.